Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	Related Studies

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

This study has been completed.
Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00031733

Locations


United States, California
	USC/Norris Comprehensive Cancer Center and Hospital
	Los Angeles, California, United States, 90089

Sponsors and Collaborators

Norris Comprehensive Cancer Center

National Cancer Institute (NCI)

Investigators


Study Chair:	Jeffrey S. Weber, MD, PhD	Norris Comprehensive Cancer Center